DK0994721T3 - Nervevækstfaktor som vaccineadjuvans - Google Patents

Nervevækstfaktor som vaccineadjuvans

Info

Publication number
DK0994721T3
DK0994721T3 DK98919999T DK98919999T DK0994721T3 DK 0994721 T3 DK0994721 T3 DK 0994721T3 DK 98919999 T DK98919999 T DK 98919999T DK 98919999 T DK98919999 T DK 98919999T DK 0994721 T3 DK0994721 T3 DK 0994721T3
Authority
DK
Denmark
Prior art keywords
vaccine
growth factor
nerve growth
animal
vaccine adjuvant
Prior art date
Application number
DK98919999T
Other languages
English (en)
Inventor
Maria Torcia
Original Assignee
Protechtion Unltd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protechtion Unltd Inc filed Critical Protechtion Unltd Inc
Application granted granted Critical
Publication of DK0994721T3 publication Critical patent/DK0994721T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK98919999T 1997-05-01 1998-04-30 Nervevækstfaktor som vaccineadjuvans DK0994721T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84722897A 1997-05-01 1997-05-01
PCT/US1998/008652 WO1998048832A1 (en) 1997-05-01 1998-04-30 Nerve growth factor as a vaccine adjuvant

Publications (1)

Publication Number Publication Date
DK0994721T3 true DK0994721T3 (da) 2007-04-02

Family

ID=25300123

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98919999T DK0994721T3 (da) 1997-05-01 1998-04-30 Nervevækstfaktor som vaccineadjuvans

Country Status (14)

Country Link
US (1) US6572866B1 (da)
EP (1) EP0994721B1 (da)
JP (1) JP4205172B2 (da)
CN (1) CN1128637C (da)
AT (1) ATE346606T1 (da)
AU (1) AU727652B2 (da)
CA (1) CA2289040A1 (da)
CY (1) CY1107571T1 (da)
DE (1) DE69836543T2 (da)
DK (1) DK0994721T3 (da)
ES (1) ES2278411T3 (da)
NO (1) NO326022B1 (da)
PT (1) PT994721E (da)
WO (1) WO1998048832A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011203139B2 (en) * 1998-02-27 2014-06-19 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
AT408721B (de) * 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
CA2530062A1 (en) * 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
CN101151049A (zh) * 2004-06-15 2008-03-26 纽约血液中心有限公司 旋盘尾丝虫的天然产物的佐剂和免疫加强性能
ATE413890T1 (de) * 2004-07-23 2008-11-15 Advisys Inc Wachstumshormon-freisetzendes hormon verstärkt die vakzin-induzierte immunantwort
WO2006116053A1 (en) * 2005-04-22 2006-11-02 Sciclone Pharmaceuticals, Inc. Immunomodulator compounds as vaccine enhancers
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
DK2535428T3 (da) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biologisk prøvesamlings- og transportsystem, og fremgangsmåder til anvendelse
US8321012B2 (en) 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject
CA3207612A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
ES2699410T3 (es) * 2014-05-28 2019-02-11 Univ Dresden Tech Ensayo basado en células y métodos de cribado de moduladores de la señalización de p75NTR
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant

Also Published As

Publication number Publication date
NO995236L (no) 1999-12-10
DE69836543T2 (de) 2007-09-20
DE69836543D1 (de) 2007-01-11
EP0994721B1 (en) 2006-11-29
CY1107571T1 (el) 2013-03-13
EP0994721A1 (en) 2000-04-26
CN1128637C (zh) 2003-11-26
ES2278411T3 (es) 2007-08-01
NO326022B1 (no) 2008-09-01
AU7266498A (en) 1998-11-24
PT994721E (pt) 2007-03-30
CN1260722A (zh) 2000-07-19
EP0994721A4 (en) 2003-08-27
JP4205172B2 (ja) 2009-01-07
CA2289040A1 (en) 1998-11-05
JP2002500638A (ja) 2002-01-08
ATE346606T1 (de) 2006-12-15
AU727652B2 (en) 2000-12-21
NO995236D0 (no) 1999-10-26
WO1998048832A1 (en) 1998-11-05
US6572866B1 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
CY1107571T1 (el) Αυξητικος παραγοντας νευρων ως βοηθητικη ουσια εμβολιου
EP0855918A4 (en) INTERLEUKIN-15 FROM CHICKEN AND USES THEREOF
CO5070644A1 (es) Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante
DE68924162T2 (de) Stressproteine und verwendungen dafür.
LU92262I2 (fr) Vaccin méningococcique groupe B (ADNr, composant, adsorbé) et ses dérivés pharmaceutiquement acceptables (BEXSERO)
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
DE69939747D1 (de) Verfahren von dna-impfung
NO950739L (no) Vaksiner mot gruppe C Neisseria Meningtidis
EP0722338A4 (en) PROTEIN OR PEPTIDE COCHLEATE VACCINES AND IMMUNIZATION METHODS USING THE SAME
IL173481A0 (en) Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration
ATE284613T1 (de) Polynukleotid-impfstoff-formulierungen
BR9815404A (pt) Composição adjuvante para estimular uma eficiente resposta imunológica a uma substância antigênica, vacina para administração a um animal, processo para estimular uma resposta imunológica eficaz em um animal a uma substância antigênica, e, uso da composição adjuvante.
FI875015A0 (fi) Vaccin mot juverinflammation.
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
BR9808878A (pt) Imunização contra moléculas endógenas